Inhibition of Aldose Reductase In Vitro by Constituents of Ganoderma lucidum

Abstract

CHCl₃ extract of the fruiting body of Ganoderma lucidum was found to show inhibitory activity on human aldose reductase in vitro. From the acidic fraction, potent human aldose reductase inhibitors, ganoderic acid C2 (1) and ganoderenic acid A (2), were isolated together with three related compounds. It was found that the free carboxyl group of ganoderic acid C2 and ganoderenic acid A is essential in eliciting the inhibitory activity considering the much lower activity of their methyl esters.

Key words

Ganoderma lucidum - Ganodermataceae - aldose reductase inhibitor - ganoderic acid - triterpenoid

References

• 1 Young R J, Ewing D J, Clarke B F. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy.  Diabetes. 1983;  32 938-942
• 2 Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy.  Kidney Int Suppl. 2000;  77 S3-S12
• 3 Frank R N, Keirn R J, Kennedy A, Frank K W. Galactose induced retinal capillary basement membrane thickening, prevention by sorbinil.  Invest Opthalmol Vis Sci. 1983;  24 1519-1524
• 4 Robinson Jr W G, Nagata M, Laver N, Hohman T C, Kinoshita J H. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.  Invest Opthalmol Vis Sci. 1989;  30 2285-2292
• 5 Bhatnagar A, Srivastava S K. Aldose reductase: congenial and injurious profiles of an enigmatic enzyme.  Biochem Med Metab Biol. 1992;  48 91-121
• 6 Patterson R R M. Ganoderma – a theraupetic fungal biofactory.  Phytochemistry. 2006;  67 1985-2001
• 7 Fatmawati S, Kurashiki K, Takeno S, Kim Y, Shimizu K, Sato M, Imaizumi K, Takahashi K, Kamiya S, Kaneko S, Kondo R. The inhibitory effect on aldose reductase by an extract of Ganoderma lucidum.  Phytother Res. 2009;  23 28-32
• 8 Hikino H, Konno C, Mirin Y, Hayashi T. Isolation and hypoglycemic activity of ganoderans A and B, glycans of Ganoderma lucidum fruit bodies.  Planta Med. 1985;  51 339-340
• 9 Min B S, Gao J J, Hattori M, Lee H K, Kim Y H. Anticomplement activity of terpenoids from the spores of Ganoderma lucidum.  Planta Med. 2001;  67 811-814
• 10 Ha T B T, Gerhäuser C, Zhang W D, Ho-Chong-Line N, Fourasté I. New lanostanoids from Ganoderma lucidum that induce NAD(P)H : Quinone oxidoreductase in cultured hepalclc7 murine hepatoma cells.  Planta Med. 2000;  66 681-684
• 11 Koyama K, Imaizumi K, Akiba M, Kinoshita K, Takahashi K, Suzuki A, Yano S, Horie S, Watanabe K, Naoi Y. Antinociceptive components of Ganoderma lucidum.  Planta Med. 1997;  63 224-227
• 12 Liu J, Shiono J, Shimizu K, Kondo R. Ganoderic acids from Ganoderma lucidum: inhibitory activity of osteoclastic differentiation and structural criteria.  Planta Med. DOI: 10.1055/s-0029-1186035 , online publication 8 October 2009
  
• 13 Gao J J, Nakamura N, Min B S, Hirakawa A, Zuo F, Hattori M. Quantitative determination of bitter principles in specimens of Ganoderma lucidum using high-performance liquid chromatography and its application to the evaluation of Ganoderma products.  Chem Pharm Bull. 2004;  52 688-695
• 14 Ma J, Ye Q, Hua Y, Zhang D, Cooper R, Chang M N, Chang J Y, Sun H H. New lanostanoids from the mushroom Ganoderma lucidum.  J Nat Prod. 2002;  65 72-75
• 15 Lee S H, Shim S H, Kim J S, Shin K H, Kang S S. Aldose reductase inhibitors from the fruiting bodies of Ganoderma applanatum.  Biol Pharm Bull. 2005;  28 1103-1105
• 16 Lee S H, Shim S H, Kim J S, Kang S S. Constituents from the fruiting bodies of Ganoderma applanatum and their aldose reductase inhibitory activity.  Arch Pharm Res. 2006;  29 479-483
• 17 Urzhumtsev A, Favier F T, Mitschler A, Barbanton J, Barth P, Urzhumtseva L, Biellmann J F, Podjarny A D, Moras D. A ‘specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.  Structure. 1997;  5 601-612
• 18 Wang X, Liu R, Sun J, Guan S, Yang M, Bi K, Guo D. HPLC method for the determination and pharmacokinetic studies of four triterpenoids in rat plasma after oral administration of Ganoderma lucidum extract.  Biomed Chromatogr. 2007;  21 389-396
• 19 Kikuchi T, Kanomi S, Kadota S, Murai Y, Tsubono K, Ogita Z. Constituents of the fungus Ganoderma lucidum (Fr.) Karst. I. Structures of ganoderic acid C2, E, I, and K, lucidenic acid F and related compounds.  Chem Pharm Bull. 1986;  34 3695-3712
• 20 Komoda Y, Nakamura H, Ishihara S, Uchida M, Kohda H, Yamazaki K. Structures of new terpenoid constituents of Ganoderma lucidum (Fr.) Karst (Polyporaceae).  Chem Pharm Bull. 1985;  33 4829-4835
• 21 Kubota T, Asaka Y, Miura I, Mori H. Structures of ganoderic acid A and B, two new lanostane type bitter triterpenes from Ganoderma lucidum (Fr.) Karst.  Helv Chim Act. 1982;  62 611-619
• 22 Nishimura C, Yamaoka T, Mizutani M, Yamashita K, Akera T, Tanimoto T. Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system.  Biochim Biophys Act. 1991;  1078 171-178